Rocket Doctor AI (AIDR) Q3 2025 earnings summary

Executive summary

• Q3 revenue grew sequentially despite summer seasonality; post-acquisition platform growth and new U.S. payer access to over 13 million members underpin expansion plans.

• The U.S. currently contributes ~5% of revenue; announced payer agreements and planned marketing are intended to accelerate U.S. growth in 2026.

Financial highlights

• Q3 2025 revenue was $529,123 vs $512,756 in Q2 2025 and $10,990 in Q3 2024; Rocket Doctor Inc. reported 20% YoY growth for the comparable quarter.

• Q3 gross margin was 88% vs 89% in Q2 2025 and 0% in Q3 2024, largely reflecting digital platform and marketplace revenue.

• Q3 net comprehensive loss was $3.5M, or $0.05/share, vs $2.7M, or $0.04/share, in Q2 and $1.6M, or $0.03/share, in Q3 2024.

• 9M 2025 revenue was $1.042M vs $11,000 in 9M 2024; net comprehensive loss was $8.353M vs $5.312M.

Outlook and guidance

• Initial revenue from U.S. payer agreements is expected to appear in Q1 2026; deployments are expected to add growth in late 2025 and 2026.

• December 2025 advertising campaigns and additional U.S. payer contracts in the Q4 pipeline are expected to support 2026 financial metrics.

• A NIH SBIR award could provide Treatment USA with over US$500,000 for medical-history data development; the project is scheduled to begin in late 2025.